Kura Oncology will host two virtual events discussing preclinical FTI data and clinical insights from ESMO Congress 2025.
Quiver AI Summary
Kura Oncology, Inc. has announced two virtual investor and analyst events focusing on its farnesyl transferase inhibitor (FTI) program. The first event on September 16, 2025, will present preclinical data revealing the potential synergies of combining FTIs with various targeted therapies, including tyrosine kinase, RAS, and PI3K alpha inhibitors, aimed at treating solid tumors. The second event on October 18, 2025, will discuss clinical data from the 2025 ESMO Congress, showcasing initial insights from KO-2806, Kura's next-generation FTI, particularly its role in overcoming cancer resistance mechanisms. Kura is committed to developing precision medicines for cancer treatment and will provide live audio webcasts and archived replays of both events on its website.
Potential Positives
- Hosting two virtual investor and analyst events highlights Kura Oncology's commitment to transparency and engagement with stakeholders.
- The focus on preclinical data and clinical insights underscores the company's leadership in cancer therapy development, particularly in targeting cancer signaling pathways.
- The presentation of first clinical data from KO-2806 at ESMO Congress 2025 demonstrates progress in addressing unmet medical needs and advancing cancer treatment options.
Potential Negatives
- The press release emphasizes the potential of FTIs to transform treatment for solid tumors, yet it acknowledges significant risks related to the efficacy and safety of these compounds in later studies, which could undermine investor confidence.
- The company is in the clinical stage, indicating that it has not yet secured regulatory approval for its product candidates, which raises concerns about the future viability of its pipeline.
- Forward-looking statements contained in the release highlight uncertainties that could cause actual results to differ materially from expectations, which may negatively impact market perception of Kura Oncology’s prospects.
FAQ
What is the focus of Kura Oncology's September 16 event?
The September 16 event will highlight the preclinical data on FTI agents combined with targeted therapies for solid tumors.
When will Kura's October 18 event take place?
The October 18 event will be held at 10:30 a.m. PT / 1:30 p.m. ET to discuss clinical data from the ESMO Congress 2025.
What data will be presented on KO-2806 at the October event?
The event will showcase the first clinical data from KO-2806, Kura's next-generation FTI, addressing resistance mechanisms in cancer.
How can I access the live webcasts of Kura's events?
Live audio webcasts will be available in the Investors section of Kura’s website during the events.
Where can we find the posters presented at ESMO Congress 2025?
The posters will be available in the “Pipeline/Posters and Presentations” section on Kura’s website post-event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KURA Insider Trading Activity
$KURA insiders have traded $KURA stock on the open market 5 times in the past 6 months. Of those trades, 2 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $KURA stock by insiders over the last 6 months:
- TROY EDWARD WILSON (President and CEO) has made 2 purchases buying 50,000 shares for an estimated $303,201 and 0 sales.
- FAHEEM HASNAIN sold 22,682 shares for an estimated $181,456
- KATHLEEN FORD (Chief Operating Officer) sold 1,558 shares for an estimated $9,777
- TERESA BROPHY BAIR (Chief Legal Officer) sold 1,559 shares for an estimated $9,291
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KURA Hedge Fund Activity
We have seen 112 institutional investors add shares of $KURA stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- RA CAPITAL MANAGEMENT, L.P. removed 4,004,610 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $23,106,599
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 2,627,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $15,157,789
- AVORO CAPITAL ADVISORS LLC removed 2,250,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $14,850,000
- ECOR1 CAPITAL, LLC added 1,559,702 shares (+59.1%) to their portfolio in Q2 2025, for an estimated $8,999,480
- SIREN, L.L.C. removed 1,339,942 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $8,843,617
- BLACKROCK, INC. added 1,292,687 shares (+15.8%) to their portfolio in Q2 2025, for an estimated $7,458,803
- FRANKLIN RESOURCES INC removed 1,262,452 shares (-80.7%) from their portfolio in Q2 2025, for an estimated $7,284,348
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KURA Analyst Ratings
Wall Street analysts have issued reports on $KURA in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 08/11/2025
- Cantor Fitzgerald issued a "Overweight" rating on 06/26/2025
- Wedbush issued a "Outperform" rating on 06/20/2025
- Mizuho issued a "Outperform" rating on 05/19/2025
- Barclays issued a "Overweight" rating on 05/02/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/28/2025
To track analyst ratings and price targets for $KURA, check out Quiver Quantitative's $KURA forecast page.
$KURA Price Targets
Multiple analysts have issued price targets for $KURA recently. We have seen 6 analysts offer price targets for $KURA in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Reni J. Benjamin from JMP Securities set a target price of $24.0 on 08/11/2025
- Robert Driscoll from Wedbush set a target price of $36.0 on 06/20/2025
- Mara Goldstein from Mizuho set a target price of $30.0 on 05/19/2025
- Peter Lawson from Barclays set a target price of $11.0 on 05/02/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $40.0 on 04/28/2025
Full Release
September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies
October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806
SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analyst events to spotlight its innovative farnesyl transferase inhibitor (FTI) program. These events will underscore Kura’s leadership in targeting cancer signaling pathways to address unmet needs in solid tumors and hematologic malignancies.
Event Details:
-
FTI Preclinical Program Review: Synergistic Combinations with Targeted Therapies
Tuesday, September 16, 2025
1:30 p.m. PT / 4:30 p.m. ET
This event will explore the scientific foundation, mechanisms of action and preclinical data supporting the combination of FTIs with tyrosine kinase inhibitors (TKIs), RAS inhibitors, and PI3K alpha inhibitors, highlighting their potential to transform treatment for solid tumors.
-
Discussion of Clinical Data Presented at 2025 ESMO Congress, Including First Clinical Data from KO-2806, Kura’s Next-Generation FTI
Saturday, October 18, 2025
10:30 a.m. PT / 1:30 p.m. ET
This event will dive into clinical data presented at the 2025 European Society for Medical Oncology (ESMO) Congress, including the first clinical insights from KO-2806, Kura’s next-generation FTI, showcasing its potential to address resistance mechanisms in cancer.
Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/ , with archived replays available following both events.
Details of the presentations at ESMO Congress 2025 are as follows:
Farnesyltransferase inhibitor (FTI) KO-2806 in combination with cabozantinib (cabo) in renal cell carcinoma (RCC): Preliminary results from FIT-001 phase 1 trial
Saturday, October 18, 2025; 12:00 PM CEST
Publication Number 2604P
A phase 1 study of the next-generation farnesyltransferase inhibitor (FTI) KO-2806 as monotherapy in advanced solid tumors
Sunday, October 19, 2025; 12:00 PM CEST
Publication Number 981P
Tipifarnib (TIP) and alpelisib (ALP) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 1 results from KURRENT-HN
Monday, October 20, 2025; 12:00 PM CEST
Publication Number 1349P
The three posters presented at ESMO Congress 2025 will be available to view in the “Pipeline/Posters and Presentations” section on Kura’s website at approximately 12:05 a.m. PT / 3:05 a.m. ET on October 18, 2025.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn .
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of FTIs to transform treatment for solid tumors and to address resistance mechanisms in cancer. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors and media:
Greg Mann
858-987-4046
[email protected]
